Medullary thyroid carcinoma: Ethical issues for the surgeon

Annals of Surgical Oncology

Volumn 19, Issue 7, 2012, Pages 2102-2107

  Shuman, Andrew G ^a,b   Shaha, Ashok R ^a   Tuttle, R Michael ^a   Fins, Joseph J ^b   Morris, Luc G T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; DOCTOR PATIENT RELATION; FAMILIAL CANCER; FAMILY; FAMILY DECISION MAKING; GENETIC RISK; GENETIC SCREENING; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; PATIENT ABANDONMENT; PATIENT AUTONOMY; PROPHYLAXIS; REVIEW; SURGEON; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADULT; CHILD; CONFIDENTIALITY; DECISION MAKING; DISCLOSURE; ETHICS, MEDICAL; FAMILY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84865129062     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2235-4     Document Type: Review

References (40)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638-48. (Pubitemid 29019586)
2. Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. 2007;33:493-7. (Pubitemid 46586095)
3. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforminggene, ret, byDNA rearrangement.Cell. 1985;42:581-8. (Pubitemid 16091150)
4. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol. 1999;17:380-93. (Pubitemid 29022417)
5. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-71. (Pubitemid 33152604)
6. Edge SB; American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
7. Lips CJ, Hoppener JW, Thijssen JH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem. 2001;38(Pt. 3):168-79. (Pubitemid 32429998)
8. Shaha AR, Cohen T, Ghossein R, Tuttle RM. Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members. Laryngoscope. 2006;116:1704-7. (Pubitemid 44368100)
9. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565-612.
10. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H. Advances in the management of hereditary medullary thyroid cancer. J Intern Med. 2005;257:50-9. (Pubitemid 40129126)
11. Rosenthal MS, Diekema DS. Pediatric ethics guidelines for hereditary medullary thyroid cancer. Int J Pediatr Endocrinol. 2011;2011:847603.
12. Buchanan A. Mental capacity, legal competence and consent to treatment. J R Soc Med. 2004;97:415-20. (Pubitemid 39279077)
13. Offit K, Groeger E, Turner S, Wadsworth EA, Weiser MA. The ''duty to warn'' a patient's family members about hereditary disease risks. JAMA. 2004;292:1469-73. (Pubitemid 39258340)
14. Giarelli E. Bringing threat to the fore: participating in lifelong surveillance for genetic risk of cancer. Oncol Nurs Forum. 2003;30:945-55.
15. Freyer G, Dazord A, Schlumberger M, Conte-Devolx B, Ligneau B, Trillet-Lenoir V, et al. Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: a multicentric pilotevaluation. Ann Oncol. 1999;10:87-95. (Pubitemid 29090597)
16. Demmer LA, O'Neill MJ, Roberts AE, Clay MC. Knowledge of ethical standards in genetic testing among medical students, residents, and practicing physicians. JAMA. 2000;284:2595-6.
17. Sulmasy DP. On warning families about genetic risk: the ghost of Tarasoff. Am J Med. 2000;109:738-9. (Pubitemid 32013024)
18. ASHG statement. Professional disclosure of familial genetic information. The American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure. Am J Hum Genet. 1998;62:474-83.
19. Tarasoff v. Regents of California, 17 Cal.3d 425 (Cal. 1976).
20. Pate v. Threlkel 661 So. 2d 278 (Fla. 1995).
21. Safer v. Estate of Pack, 291 N.J. Super. 619 (Sup. N.J. 1996).
22. American Medical Association. Opinion 2.131: Disclosure of familial risk in genetic testing. Code of medical ethics. 2003. http://www.ama-assn.org/ama/ pub/physician-resources/medical-ethics/code-medical-ethics/opinion2131.shtml.
23. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893-901.
24. Godard B, Hurlimann T, Letendre M, Egalite N. Guidelines for disclosing genetic information to family members: from development to use. Fam Cancer. 2006;5:103-16. (Pubitemid 43384325)
25. Gostin LO. National health information privacy: regulations under the Health Insurance Portability and Accountability Act. JAMA. 2001;285:3015-21. (Pubitemid 32550121)
26. Fleisher LD, Cole LJ. The Health Insurance Portability and Accountability Act is here: what price privacy? Genet Med. 2001; 3:286-9.
27. Falk MJ, Dugan RB, O'Riordan MA, Matthews AL, Robin NH. Medical geneticists' duty to warn at-risk relatives for genetic disease. Am J Med Genet A. 2003;120A:374-80. (Pubitemid 37063773)
28. Rosenthal MS, Pierce HH. Inherited medullary thyroid cancer and the duty to warn: revisiting Pate v. Threlkel in light of HIPAA. Thyroid. 2005;15:140-5. (Pubitemid 40344362)
29. Ridley DT. Informed consent, informed refusal, informed choice-what is it that makes a patient's medical treatment decisions informed? Med Law. 2001;20:205-14. (Pubitemid 32640221)
30. Dunham J. Deciding for others: the ethics of surrogate decision making. Library J. 1990;115:188.
31. Byrd S, Shuman AG, Kileny S, Kileny PR. The right not to hear: the ethics of parental refusal of hearing rehabilitation. Laryngoscope. 2011;121:1800-4.
32. Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994;220:237-47.
33. van Heurn LW, Schaap C, Sie G, Haagen AA, Gerver WJ, Freling G, et al. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidec-tomy in very young children. J Pediatr Surg. 1999;34:568-71. (Pubitemid 29183789)
34. Telander RL, Zimmerman D, Sizemore GW, van Heerden JA, Grant CS. Medullary carcinoma in children. Results of early detection and surgery. Arch Surg. 1989;124:841-3. (Pubitemid 19181033)
35. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol. 2006; 155:229-36. (Pubitemid 44269439)
36. Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93:3058-65.
37. Hord JD, Rehman W, Hannon P, Anderson-Shaw L, Schmidt ML. Do parents have the right to refuse standard treatment for their child with favorable-prognosis cancer? Ethical and legal concerns. J Clin Oncol. 2006;24:5454-6. (Pubitemid 46655917)
38. Parker M. Genetic testing in children and young people. Fam Cancer. 2010;9:15-8.
39. Dubler NN, Marcus LJ. Mediating bioethical disputes. New York: United Hospital Fund of New York; 1994.
40. Grosfeld FJ, Beemer FA, Lips CJ, Hendriks KS, ten Kroode HF. Parents' responses to disclosure of genetic test results of their children. Am J Med Genet. 2000;94:316-23.